# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Judy Garland (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML005-SYN-TD
- Date: 1955-07-20
- Fictional facility: St. Posthumous Health Center
- Fictional author: Margaret Ellsworth-Diaz, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Four-week review, eleven days after the supervised change to phenobarbital. **S**

## History of present illness

Ms. Garland returns eleven days after a four-day admission to the addiction medicine service. Secobarbital was stopped on admission and phenobarbital was started and adjusted with withdrawal scoring; she had a mild tremor and poor sleep on the second night, no seizure and no confusion, and she was discharged on phenobarbital 32.4 mg three times daily. She has taken it as prescribed from the one-week supply and has taken no secobarbital. She was drowsy for the first three days at home, and that has passed. She sleeps four to five hours a night; her sleep diary shows that she lies awake for an hour after late rehearsals. She has kept to one 10 mg dextroamphetamine tablet each morning. She has taken sertraline 50 mg daily without side effects. Her mood is a little better. The dietitian could not see her yet because of a waiting list. **S**

| Element | Detail |
|---|---|
| Admission | Four days; mild tremor on one night; no seizure or delirium |
| Phenobarbital | 32.4 mg three times daily since discharge |
| Secobarbital | None since admission |
| Sleep | Four to five hours; Insomnia Severity Index 18 |
| Dextroamphetamine | 10 mg each morning |
| Mood | PHQ-9 12; GAD-7 11 |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Drowsiness after discharge has passed; no fever |
| Neurological | Negative | No tremor, unsteadiness or seizure-like episodes since discharge |
| Psychiatric | Positive | Mood low at times, better than at intake; no thoughts of suicide or self-harm |

3 systems reviewed. **S**

## Current medications

- Dextroamphetamine 5 mg oral tablet, one tablet each morning for two weeks, then stop **S**
- Sertraline 50 mg oral tablet, one tablet daily **S**
- Phenobarbital 16.2 mg oral tablet on a written taper schedule in two or three divided doses: 81 mg a day from the four-week visit, lowered by 8.1 to 16.2 mg about every two weeks and paused when needed; dispensed two weeks at a time **S**
- Medroxyprogesterone acetate 150 mg/mL injection, 150 mg into the muscle every 13 weeks **S**

## Allergies

- No known allergy **S**

## Objective

BP 118/76 mmHg; pulse 82 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 47.6 kg; BMI 20.9 kg/m². All vital signs are synthetic.

PHQ-9: 12; GAD-7: 11. All results are synthetic.

## Change since baseline

- PHQ-9: 14 at baseline, 12 at this visit **S**
- GAD-7: 13 at baseline, 11 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 118/76, pulse 82; weight 47.6 kg |
| Neurological | No tremor or nystagmus; finger-to-nose and gait normal |
| Psychiatric | Engaged; no signs of sedation or withdrawal |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Barbiturate use disorder on phenobarbital** (F13.20). Stable on 97.2 mg a day with no withdrawal and no sedation, so the outpatient taper can begin. Urine test shows barbiturates, as expected on phenobarbital, and amphetamine. Safety reviewed: no thoughts of suicide or self-harm; supply locked away. **S**
   - Phenobarbital 16.2 mg tablets on the written taper schedule: 81 mg a day from today (32.4 mg morning, 16.2 mg afternoon, 32.4 mg at bedtime), then 64.8 mg a day in two weeks if she is well, with a nurse phone check before each step.
   - Dispensed two weeks at a time.
   - Call the same day for tremor, sweating, confusion or a seizure.
2. **Stimulant use disorder (prescribed amphetamine), mild** (F15.10). Barbiturate now stable, so the stimulant taper starts as planned. **S**
   - Dextroamphetamine 5 mg each morning for two weeks, then stop.
   - Expect tiredness and more sleep for a week or two; regular meals and daylight walks help.
3. **Chronic insomnia** (G47.00). Sleep short, as expected early in the taper. CBT-I has begun. **S**
   - A fixed wake time, a wind-down hour after late rehearsals, and out of bed when unable to sleep; sleep restriction to wait until the taper is further along.
4. **Depression with anxious distress on sertraline** (F32.1). PHQ-9 12 from 14, GAD-7 11 from 13; early improvement three weeks after reaching 50 mg. **S**
   - Continue sertraline 50 mg daily and weekly psychotherapy.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Medication safety | Barbiturate dose, adherence, extra doses, and withdrawal signs (tremor, sweating, pulse, sleep, seizure warning signs) | Every visit | Completed today | Phenobarbital 97.2 mg a day since discharge; no secobarbital; no withdrawal or sedation |
| Referral | Setting for barbiturate withdrawal | Before any reduction | Completed today | Four-day supervised admission completed without a seizure or delirium |
| Medication safety | Taper pace | Reductions of no more than about 20% every two weeks, slower toward the end; pause for symptoms, illness or a major performance | Completed today | First step today, 97.2 to 81 mg a day (17%) |
| Medication safety | Prescription drug monitoring program check | Before every controlled-substance prescription | Completed today | Only the hospital's and this clinic's prescriptions |
| Laboratory | Urine drug testing, explained as part of care | At the start, after the change to phenobarbital, and periodically during the taper | Completed today | Barbiturates and amphetamine, as prescribed; nothing else |
| Medication safety | Limited dispensing, locked storage and take-back of unused capsules | Seven days at first, then two weeks at a time | Completed today | Two-week supply from today; locked box |
| Medication safety | Stimulant dose, extra doses, cravings, and blood pressure and pulse | Every visit | Completed today | 10 mg each morning, no extra doses; blood pressure 118/76, pulse 82; taper to 5 mg started |
| Examination | Electrocardiogram | Before continuing a stimulant | Up to date | Normal at intake |
| Survey | CBT for insomnia, sleep diary and Insomnia Severity Index | Weekly CBT-I sessions; sleep diary and index at each visit | Completed today | Two CBT-I sessions; Insomnia Severity Index 18 |
| Medication safety | New hypnotic (benzodiazepine, Z-drug, trazodone or antihistamine) | Not recommended as a replacement | Not indicated | No new hypnotic |
| Survey | Depression (PHQ-9) | At least monthly during acute treatment | Completed today | PHQ-9 12, item 9 scored 0 |
| Survey | Anxiety (GAD-7) | With each PHQ-9 while anxiety is treated | Completed today | GAD-7 11 |
| Medication safety | Sertraline adherence and side effects | Two weeks after starting or changing the dose, then each visit | Completed today | 50 mg daily for three weeks; no side effects |
| Survey | Suicide-risk review (C-SSRS screen since the last visit), safety plan, means safety and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | C-SSRS screen negative since the last visit; safety plan reviewed; the 988 Suicide & Crisis Lifeline in her phone |
| Self-management | Psychotherapy | Weekly | Completed today | Weekly sessions continuing |
| Examination | Weight, meals and disordered-eating screen, without a weight target | Every visit | Completed today | Weight 47.6 kg, up 1.1 kg; two meals a day |
| Referral | Dietitian visit | Within a month of intake | Deferred | Not yet seen four weeks after intake because of a waiting list. No harm so far: weight is rising and she is eating more. Corrective action: the clinic booked a second dietitian with an earlier opening |
| Medication safety | Contraception that phenobarbital does not weaken | Medroxyprogesterone every 13 weeks | Up to date | First injection at intake; next due in about nine weeks |
| Medication safety | Naloxone | Reassess at every visit and whenever an opioid is prescribed | Not indicated | No opioids prescribed or used |
| Self-management | Work schedule and driving safety | With each dose change | Completed today | No driving while drowsy; taper steps planned for weeks without major performances |

## Goal progress

- Change from secobarbital to phenobarbital under supervision without a withdrawal seizure or delirium. Outcome by 1955-07-20: Four-day supervised admission; no seizure, delirium or severe withdrawal. **S**
- Lower the phenobarbital dose slowly, at no more than about 20% every two weeks, toward stopping. In progress; target 1955-10-26. **S**
- Stop dextroamphetamine with a short taper and no return to it. In progress; target 1955-08-31. **S**
- Sleep six hours or more on most nights using CBT for insomnia. In progress; target 1955-10-26. **S**
- PHQ-9 below 5 by six months. In progress; target 1955-10-26. **S**
- Regular meals and weight she is comfortable with, without dieting drugs. In progress; target 1955-10-26. **S**

## Medication changes

- Stopped: Dextroamphetamine 10 mg oral tablet, one tablet each morning; no extra doses; prescribed elsewhere for weight and energy **S**
- Started: Dextroamphetamine 5 mg oral tablet, one tablet each morning for two weeks, then stop **S**
- Stopped: Phenobarbital 32.4 mg oral tablet, one tablet three times daily (97.2 mg a day), started in hospital in place of secobarbital **S**
- Started: Phenobarbital 16.2 mg oral tablet on a written taper schedule in two or three divided doses: 81 mg a day from the four-week visit, lowered by 8.1 to 16.2 mg about every two weeks and paused when needed; dispensed two weeks at a time **S**

## Guideline basis

- Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025), American Society of Addiction Medicine and nine partner organizations (J Gen Intern Med 2025;40(12):2814-2859)
- The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management (2020), American Society of Addiction Medicine (Journal of Addiction Medicine)
- The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2024), American Society of Addiction Medicine and American Academy of Addiction Psychiatry (Journal of Addiction Medicine)
- Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline (2017), American Academy of Sleep Medicine (Journal of Clinical Sleep Medicine)
- Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians (2016), American College of Physicians (Annals of Internal Medicine)
- U.S. Medical Eligibility Criteria for Contraceptive Use, 2024 (2024), Centers for Disease Control and Prevention (MMWR Recommendations and Reports)
- Prescription Drug Monitoring Programs (PDMPs) (2026), Centers for Disease Control and Prevention
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026), Aether Forge

## Follow-up

- Nurse phone check before each taper step. Ten-week review in six weeks. Weekly psychotherapy and CBT-I. **S**
- Next scheduled visit 1955-08-31: ten-week review: phenobarbital taper, life after stopping the stimulant, sleep, mood, weight and work. **S**
